BiotechTube

PDE5 Inhibitors

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nonarteritic Anterior Ischemic Optic Neuropathy

Conditions

Nonarteritic Anterior Ischemic Optic Neuropathy

Trial Timeline

May 1, 2010 → Dec 1, 2015

NCT ID
NCT01131104

About PDE5 Inhibitors

PDE5 Inhibitors is a pre-clinical stage product being developed by Eli Lilly for Nonarteritic Anterior Ischemic Optic Neuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01131104. Target conditions include Nonarteritic Anterior Ischemic Optic Neuropathy.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01131104Pre-clinicalCompleted

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85